<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00793663</url>
  </required_header>
  <id_info>
    <org_study_id>ALS-8-08-A-401</org_study_id>
    <secondary_id>EudraCT-number:</secondary_id>
    <secondary_id>2008-004132-20</secondary_id>
    <secondary_id>Protocol version:</secondary_id>
    <secondary_id>Version V3; Date: 20.10.2008</secondary_id>
    <nct_id>NCT00793663</nct_id>
  </id_info>
  <brief_title>Depth of Hypnosis and Postoperative Nausea and Vomiting During Xenon Anaesthesia</brief_title>
  <acronym>XABP</acronym>
  <official_title>1) The Effect of Xenon and Sevoflurane on Hypnosis Monitors. 2) Prevention of Postoperative Nausea and Vomiting. 3) Rescue Treatment of Established Postoperative Nausea and Vomiting. Sevoflurane.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Air Liquide Santé International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is ad 1) to measure the depth of hypnosis as assessed by BIS and&#xD;
      cAAI during an average general anesthesia with xenon or sevoflurane and to establish a&#xD;
      reliable monitoring system for measuring and documenting the actual depth of hypnosis for the&#xD;
      volatile anesthetics investigated. Ad 2) the question is to be answered whether 4 mg&#xD;
      dexamethasone i.v. is an effective prophylactic treatment against postoperative nausea and&#xD;
      vomiting in case of xenon or sevoflurane anesthesia. Ad 3) it serves to gain evidence about&#xD;
      the (non-)effectiveness and kinetics of ondansetron as antiemetic remedy after xenon or&#xD;
      sevoflurane anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Patients included into the trial will randomly be allocated to either 0.8-1.1 minimum&#xD;
           alveolar concentration (MAC) xenon in 30 % oxygen or 0.8-1.1 MAC sevoflurane (age&#xD;
           adapted)/30 % oxygen. The MAC is defined and will therefore be applied according to the&#xD;
           investigated subject's age. Premedication will be performed with midazolam 7.5 mg orally&#xD;
           45 min before induction (standard dose and application form for adults as clinical&#xD;
           practice of our department). Anesthesia will be induced in both groups with propofol 2&#xD;
           mg/kg i.v. and remifentanil 0.5 mcg/kg/min by infusion over 60 s. For tracheal&#xD;
           intubation non-depolarizing neuromuscular blocking agents can be used (rocuronium 0.6&#xD;
           mg/kg). Both groups will receive remifentanil at a base rate of 0.2 mcg/kg/min. Xenon or&#xD;
           sevoflurane can be titrated in the range from 0.8-1.1 MAC according to clinical needs&#xD;
           based on the patient's hemodynamic, autonomic and somatic signs. Twenty minutes before&#xD;
           the estimated cessation of all surgical procedures 0.05 mg kg-1 piritramide for post&#xD;
           anesthetic pain management will be administered intravenously, as well as a short&#xD;
           infusion of metamizole 15 mg kg-1.&#xD;
&#xD;
           Depth of anesthesia (hypnosis) will be monitored with spontaneous EEG (BIS VISTA, Aspect&#xD;
           Medical Systems, Newton, MA) and the mid latency auditory evoked potentials including a&#xD;
           monitoring variable indicating the patients hypnotic state calculated from the MLAEP and&#xD;
           the electroencephalogram, the composite A-Line ARX Index (cAAI) with the AEP Monitor/2&#xD;
           (Danmeter A/S, Odense, Denmark). Dosing will be conducted according to the current&#xD;
           clinical standard without the monitoring, thus the anesthesia provider will be blinded&#xD;
           towards both measurements.&#xD;
&#xD;
        2. After induction of anesthesia patients will be randomized to a second factor, i.e. 4 mg&#xD;
           dexamethasone or placebo for the prevention of PONV. To avoid potential imbalances, this&#xD;
           will be achieved using a factorial design. The application of dexamethasone or placebo&#xD;
           will be blinded to the investigator assessing postoperative nausea and vomiting.&#xD;
&#xD;
        3. Patients who experience significant nausea will be randomized to receive either 4 mg&#xD;
           ondansetron or placebo and the course of nausea will be assessed for &gt; 32 min. Again,&#xD;
           the application of ondansetron or placebo will be blinded to the investigator assessing&#xD;
           postoperative nausea and vomiting. If the symptoms of postoperative nausea and vomiting&#xD;
           persist for more than 32 min after treatment additional rescue treatment will be&#xD;
           offered. Of note, all patients are able to receive further rescue treatment at any time&#xD;
           point of the study on demand.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The average depths of hypnosis as assessed by the BIS and the cAAI between skin incision and start of closure.</measure>
    <time_frame>During anaesthesia</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative nausea as assessed by a verbal rating scale (VRS) ranging between 0 and 10.</measure>
    <time_frame>After anesthesia at 5, 10, 15, 30, 45, 60, and 90 min. At 2, 6 and 24 h after anesthesia the maximum nausea will be rated for the 30-120 min, 2-6 h, and 6-24 h interval.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of VRS nausea immediately at 2, 5, 7.5, 10, 15, 20 and 30 min after rescue treatment administration.</measure>
    <time_frame>Maximum nausea will be rated at 2, 6 and 24 hours after treatment for the 30-120 min, 2-6 h and 6-24 h interval.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate and blood pressure</measure>
    <time_frame>During anesthesia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observer´s assessment of alertness and sedation scales</measure>
    <time_frame>Recovery from anesthesia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity characteristics for both the BIS and the cAAI.</measure>
    <time_frame>During anesthesia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Awareness after anesthesia assessed by the Brice questionnaire at 2 and 24 hours after anesthesia.</measure>
    <time_frame>24 hours after anaesthesia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of postoperative vomiting and the respective time-points will be recorded. Postoperative vomiting is defined as vomiting or retching.</measure>
    <time_frame>24 hours postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage of rescue medication, time and dosage</measure>
    <time_frame>24 hours postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge from post anesthetic care unit (Aldrete Score ≥ 9 equals the hypothetic discharge time from post anesthetic care unit)</measure>
    <time_frame>Time in the post anesthetic care unit</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Anaesthetics Gases, Xenon</condition>
  <condition>Anaesthetics Volatile, Sevoflurane</condition>
  <condition>Depth of Anaesthesia</condition>
  <condition>Postoperative Nausea</condition>
  <condition>Postoperative Vomiting</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The effect of xenon as an anaesthetic on the depth of hypnosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The effect of sevoflurane as an anesthetic on the depth of hypnosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone as prevention of postoperative nausea and vomiting after xenon or sevoflurane anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ondansetron, to determine the onset-time of ondansetron when used as rescue medication for postoperative nausea and vomiting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xenon</intervention_name>
    <description>Inhalational gas; maximum dose allowed: 70 % Xenon; the duration of the treatment will be defined through anesthesia-time.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>LENOXe</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Inhalation gas; age adapted MAC-values; the duration of the treatment will be defined through anesthesia-time</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Sevorane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Intravenous use, 4 mg, single shot</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Fortecortin Inject</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl</intervention_name>
    <description>Intravenous use; single shot</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Intravenous use; 4 mg; single shot</description>
    <arm_group_label>5</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl</intervention_name>
    <description>Intravenous use; single shot</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients ≥ 18 &lt; 75 years&#xD;
&#xD;
          -  ASA physical status I-II&#xD;
&#xD;
          -  planned duration of anesthesia ≥ 60 minutes&#xD;
&#xD;
          -  Apfel score ≥ 2-3&#xD;
&#xD;
          -  elective (laparoscopic) surgery (abdominal, gynecological)&#xD;
&#xD;
          -  women: with a highly effective contraception, defined as methods with a pearl index &lt;&#xD;
             1 (i.e. hormonal contraceptives, IUD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of hypersensitivity to any used drugs or additive components used for&#xD;
             preparation and stabilization of the named drugs in this trial&#xD;
&#xD;
          -  history or reasonable suspicion of malignant hyperthermia and/or degenerative&#xD;
             neuromuscular disease, in the subject observed or blood relatives&#xD;
&#xD;
          -  history of liver function disorders, leucocytosis and unclear fever after usage of&#xD;
             halogenated anesthetics.&#xD;
&#xD;
          -  any indisposition that may be aggravated by the use of the drugs investigated:&#xD;
&#xD;
          -  liver and/or kidney function disorders&#xD;
&#xD;
          -  severe acute or chronic infectious disease (i.e. viral, bacterial, fungal)&#xD;
&#xD;
          -  elevated intracranial pressure&#xD;
&#xD;
          -  history of gastrointestinal ulcer(s) or inflammatory bowel disease&#xD;
&#xD;
          -  severe metabolic disorders&#xD;
&#xD;
          -  hematoporphyria&#xD;
&#xD;
          -  glaucoma&#xD;
&#xD;
          -  hearing disorders&#xD;
&#xD;
          -  any disease including air-filled closed cavities, such as pneumothorax, ileus&#xD;
&#xD;
          -  pregnancy and lactation period&#xD;
&#xD;
          -  subjects under the age of 18 years&#xD;
&#xD;
          -  ambulatory surgery&#xD;
&#xD;
          -  any disease that is associated with the requirement of a high oxygen yield and/or&#xD;
&#xD;
          -  risk of high oxygen consumption:&#xD;
&#xD;
          -  severe lung and/or airway disease&#xD;
&#xD;
          -  coronary heart disease and/or seriously impaired cardiac function&#xD;
&#xD;
          -  severe psychiatric disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf Rossaint, MD</last_name>
    <role>Study Chair</role>
    <affiliation>RWTH University Aachen; Department of Anesthesiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RWTH Aachen University; Department of Anesthesiology</name>
      <address>
        <city>Aachen</city>
        <zip>D-52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>November 18, 2008</study_first_submitted>
  <study_first_submitted_qc>November 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2008</study_first_posted>
  <last_update_submitted>May 16, 2011</last_update_submitted>
  <last_update_submitted_qc>May 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Mark Coburn, Principal Investigator</name_title>
    <organization>RWTH Aachen University; Department of Anesthesiology</organization>
  </responsible_party>
  <keyword>Xenon</keyword>
  <keyword>Sevoflurane</keyword>
  <keyword>Postoperative Nausea and vomiting</keyword>
  <keyword>Depth of anaesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

